Pancreatic ductal adenocarcinoma (PDAC) · line 1 · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`None`

ID	`IND-PDAC-ADJUVANT-MFOLFIRINOX`
Type	Indication
Status	reviewed 2026-05-08 \| pending_clinical_signoff \| actionability review required
Diseases	`DIS-PDAC`
Sources	`SRC-ESMO-PANCREATIC-2024` `SRC-NCCN-PANCREATIC-2025` `SRC-PRODIGE-24-CONROY-2018`

Notes

GI-3 Phase C1: §17 single-phase adjuvant indication for resected PDAC, mirroring GI-2 C1 FLOT periop pattern but adjuvant-only because surgery happened pre-enrollment in PRODIGE-24. The phases[] block contains a single chemotherapy phase (adjuvant × 12 cycles, REG-MFOLFIRINOX). The surgical pre-condition is captured in stage_requirements rather than phases[] — patients reaching this indication have already had R0/R1 resection. Engine routing from PDAC algorithm to this indication is out of C1 scope — flagged for D2 algorithm-extension chunk follow-up.

Used By

Algorithms

ALGO-PDAC-RESECTABLE-PERIOP - ALGO-PDAC-RESECTABLE-PERIOP

Indication

IND-PDAC-BORDERLINE-RESECTABLE-NEOADJ-FOLFIRINOX - IND-PDAC-BORDERLINE-RESECTABLE-NEOADJ-FOLFIRINOX